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Murine hybridoma antibodies of predetermined specificity have been of great value 
in the study of antibody diversity, in dissecting out the roles of idiotypes and anti- 
idiotypes in  immunoregulation,  and  as  reagents  for immunologic diagnoses  (1,  2). 
Monoclonal  human  hybridoma  antibodies  have  been  produced  by  the  fusion  of 
human spleen  (3, 4), lymph node  (5),  or malignant  cells  (6)  with human or mouse 
myeloma cells. These methods have not gained widespread applicability for a number 
of reasons, including the lack of practical accessibility of these lymphoid organs and/ 
or  the  undetermined  specificity of the  secreted  monoclonal  immunoglobulin  (Ig). 
Human-human  hybridomas  secreting  antimeasles  antibodies  have  been  produced 
using the peripheral blood lymphocytes of a patient with subacute sclerosing panen- 
cephalitis.  However,  the  specific  Ig  produced  in  this  manner  has  been  of mixed 
genotype, containing components of both  fusion  partners  (7).  On  the other hand, 
successful fusion has been accomplished with normal human peripheral blood lym- 
phocytes and mouse myeloma cells. Although human antibodies have been produced 
in this manner, they have been of unknown specificity and were secreted in association 
with murine Ig and mixed mouse-human Ig (8). 
We have recently developed an antigen-induced, antigen-specific in  vitro system 
for the study of specific human  B cell responses and have delineated the kinetics of 
the circulating antigen-specific B cell repertoire in normal human subjects following 
immunization with the soluble protein antigen keyhole limpet hemocyanin (KLH) 
(9,  I0). The present study reports the successful production of a hybridoma secreting 
human  monoclonal antibody of predetermined  specificity utilizing  the  peripheral 
blood lymphocytes of one of these subjects. 
Materials and Methods 
Human Hybridoma Antibody Production.  Human-mouse heterohybridomas were produced by a 
modification of the method described  by Schlom et al.  (5) for fusion of human lymph node 
cells. Unfractionated mononuclear cells were obtained by Ficoll-Hypaque gradient centrifu- 
gation of 100 ml of peripheral blood drawn from a normal volunteer 10 d after immunization 
with 5 mg of KLH (Calbiochem-Behring  Corp., American Hoechst Corp.,  San Diego, Calif.) 
as previously described  (9). These cells were fused with an equal number of the nonsecreting 
BALB/c hypoxanthine-aminopterin-thymidine (HAT)-sensitive  myeloma line  SP-1 (kindly 
provided by Dr. J. Schlom, National Cancer Institute, Bethesda,  Md.)  utilizing  polyethylene 
glycol-1500. Following fusion, cells were suspended at 107/ml in complete media, comprised of 
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RPMI 1640 plus glutamine (Flow Laboratories, Inc., Rockville, Md.), 2 pg/ml amphotericin B 
(Gibco Laboratories, Grand Island Biological Co., Grand Island, N. Y.), 70/~g/ml gentamicin 
(Schering Corp.,  Kenilworth, N. J.),  and 30% heat-inactivated fetal calf serum screened to 
support hybridoma growth (Gibco Laboratories). 100 ~1 of this suspension was added to each 
of the  inner wells  of a  96-well,  flat-bottomed microtiter plate  (Costar  3596,  Costar,  Data 
Packaging, Cambridge, Mass.). The outer wells were filled with a mixture consisting of 100 pg/ 
ml amphotericin B and 0,5 mg/ml gentamicin. The day of fusion is denoted day 0. 24 h after 
fusion, 125 pl of complete media containing  4 ×  10  -7 M aminopterin, 1 ×  10  -4 M hypoxanthine, 
and 1.6 ×  10  -5 M thymidine (all from Sigma Chemical Co., St. Louis, Mo.), hereafter referred 
to as HAT media, was added to each well. On days 2, 3, 5, 8,  11,  14,  17, and 21,  100/~1 of 
supernatant was removed from each microwell and 100/A of fresh HAT media added. 
On day 21, all supernatants were screened for nonspecifie human IgG or IgM and for IgG 
or IgM directed against KLH using enzyme-linked  immunosorbent assays (ELISA) as has been 
described previously (9, 11). Cultures secreting the desired Ig were aspirated and transferred to 
individual 16-mm wells of a 24-well culture plate (Costar 3524) containing 1 ml of complete 
media supplemented with 1 ×  10 -4 M hypoxanthine and 1.6 ×  10  -5 M thymidine (HT media). 
24 h after transfer, an additional 1 ml of HT media was added to each well. Thereafter, 1 ml 
of supernatant was exchanged for  1 ml of fresh HT media twice weekly. 
After 14 d in macrocuhure, wells were again screened for antibodies against KLH. Cell lines 
continuing  to secrete specific antibody were transferred to 75 cm  2 tissue culture flasks containing 
5 ml of complete media. Cell lines were then expanded and either frozen or used for cloning. 
The cell line with the best growth characteristics secreting the highest titer-specific antihody 
was chosen for cloning  by limiting  dilution. For the first cloning, cells were cultured in complete 
media and plated at 100, 10, or 1 cell/well in 96-well round-bottomed microtiter plates. Positive 
wells, screened at  7-14 d, were  transferred to  16-ram wells and then expanded into flasks as 
described above. They were then cloned twice at 0.5 cell/well. 
To obtain purified antibody, cloned cells were grown to confluence in RPMI 1640 supple- 
mented with 2 pg/ml amphotericin B and 70 pg/ml gentamicin, with or without 20% fetal calf 
serum. Cell suspensions were then centrifuged at  1,000 g, and the supernatants were decanted. 
The mononclonal anti-KLH antibody was  then separated,  if necessary,  from  the  fetal calf 
serum by affinity chromatography for subsequent immunologic and functional studies. 
Isoelectric Focusing.  Analytical isoelectric  focusing was  performed as  previously described 
with a  110-ml column (8100, LKB Instruments, Stockholm, Sweden) (12). A pH gradient of 
3.5-10 was constructed in a sucrose gradient (50-0% wt/vol) in 2 M urea/l% ampholytes. The 
sample (150 pl of affinity-purified antibody in phosphate-buffered saline at 0.5  mg/ml) was 
applied to the middle of the gradient. The column was run at a constant 300 V for 72 h at 4°C 
and eluted in 0.5 ml fractions. Eluted fractions were assayed for anti-KLH antibody using an 
alkaline-phosphatase ELISA with the amount of antibody present expressed  as OD40~ (absorp- 
tion of paranitrophenol). 
Double Immunodiffusion.  20/d of commercial antiserum (Meloy Laboratories, Springfield, Va. 
or N. L. Cappel Laboratories, Cochranville, Pa.) or affinity-purified hybridoma antibody was 
applied to each well of an Ouchterlony plate. Photographs were taken after a 48-h incubation 
at 4°C. 
Lymphocyte Blast Transformation.  Cultures were performed as previously described in 96-well 
microtiter dishes (Limbro Chemical Co., Hamden, Conn.) with 1 X l0  s cells/well (13). Cultures 
contained 0.2  ml  RPMI  1640 with  15%  human A  serum.  Various amounts of anti-KLH 
hybridoma antibody, pooled human IgM myeloma (N. L. Cappel Laboratories), or pokeweed 
mitogen (PWM; Gibco Laboratories) were added to the cultures that were then incubated in 
a 5% CO2 atmosphere at 37°C. Cultures were pulsed with 2 ~Ci of [3H]thymidine on day 5 and 
harvested 4 h later on a Titertek cell harvester (Flow Laboratories). The filter disks were placed 
in scintillation vials with  3  ml Aquasol scintillation fluid  (New  England Nuclear, Boston, 
Mass.)  and counted in a scintillation counter (Beckman LS-350,  Beckman Instruments, Inc., 
Spinco Div., Palo Alto, Calif.). 
Results 
On initial screening 102 of 240 wells were found to contain Ig (Table I). Eight of 
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TAnLE  I 
Human MonoclonaI Antibody Production 
Day of  Culture: number of wells plated  IgG or IgM directed  All lgG or  Cloning 
screening*  against KLH  lgM  efficiency:~ 
% 
21  Fusion-240  8 
35  Expanded KLH-positive wells--6  2(2FT,3D3) 
120  First cloning of 2F7 
10 cells/well--60  7 
100 cells/well--60  44 
150  Second cloning (2F72Cs) 
0.5 cells/well--  120  24 
160  Third cloning (2F72CslBn) 





* Day 0, day of fusion. 
~: Calculated as number of positive wells/number of wells calculated to have El cell/well. 
antibodies specific for KLH were expanded into larger plates, and two of these six 
continued to produce anti-KLH antibodies at 5 wk. The faster growing line, 2F7, was 
chosen for cloning. The initial cloning efficiency was low (<12%), and the cells had 
to be plated  at  100/well  in  order to obtain  a  rapidly growing antibody-producing 
line. Once this was achieved, however, subsequent cloning was possible at 0.5 cell/ 
well, with a cloning efficiency of 64% in the final cloning. 
The  hybridoma  antibody  produced  by  the  fusion  of human  peripheral  blood 
lymphocytes with  the  nonsecreting mouse myeloma line  SP-1  was  a  human  IgMk 
(Fig.  1 a  and b), achieving concentrations in culture as high as 30/~g/ml, No mouse 
Ig (heavy or light chain) was detectable by double immunodiffusion. Affinity-purified 
antibody  displayed  a  single  peak  on  isoelectric  focusing  with  a  pI  of 4.5,  thus 
confirming its monoclonal nature (Fig. 2). 
Addition of the monoclonal anti-KLH antibody to otherwise unstimulated cultures 
of peripheral blood mononuclear cells from individuals recently immunized to KLH 
resulted in a  substantial  blastogenic response. Although the mononuclear cells from 
nonimmunized individuals failed to proliferate in response to the monoclonal antibody 
2F7, the peripheral blood lymphocytes of subjects recently immunized to KLH showed 
a  10-fold  increase in  [3H]thymidine incorporation  in  response  to  10 /zg/ml  of 2F7 
(Table II). 
Discussion 
In the present study we describe the production of a B cell hybridoma from human 
peripheral blood lymphocytes secreting human monoclonal antibody directed against 
a  predetermined antigen  to which  an  individual  was  recently immunized,  Several 
factors were influential in our ability to achieve a stable heterohybridoma secreting 
KLH-specific antibody. It was important to take advantage of the fact that antigen- 
specific B  cells will  be contained  in  relatively high  proportions  in  the  circulating 
peripheral blood pool for only a  short time after immunization with the antigen in 
question (10,  14). Appreciation of this restriction in the time interval when antigen- 
reactive B cells are available in the circulating B cell repertoire for fusion following 
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FIe.  1.  Analysis of 2F7 antibody by double immunodiffusion.  A,  goat  anti-human  IgM  (~-chain 
specific); B, goat anti-human IgG (y-chain specific); C, goat anti-human IgA (a-chain specific); D, 
sheep  anti-human  X;  E,  goat  anti-human  k;  F,  goat  anti-mouse IgM  (,tt-chain specific); G,  rabbit 
anti-mouse IgG  (heavy and  light chain);  It,  rabbit  anti-mouse k.  Precipitin lines between wells E 
and  D  and  between  wells  B  and  C  represent  cross-reactivity  between  the  immunizing antigen 
(human  Ig) and goat or sheep Ig. 
f  /  10.0  .10 
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FIO.  2.  Isoelectric focusing of 2Fv.  Procedure  as described under  Materials and  Methods.  0.5-ml 
fractions were obtained and assayed for anti-KLH activity and pH. O, pH; O, OD405  (absorption of 
paranitrophenol in ELISA). 
TABLE  II 
Blastogenic Response of Human Lymphocytes to Human Monoclonal Anti-KLH Antibody 2F7 
Unstimulated 
Subject  KLH-immune  (background)  PWM*  2Fv~  lgM§ 
i  Yes  179 +  lO¶  9,632 +_ 562  1~349 -  194  140 ±  16 
2  Yes  1,369 +- 385  25,253 ±  637  9,795 +- 1012  1,067 +.  105 
3  No  345 +- 36  11,672 ±  1316  182 +- 25  289 +. 50 
4  No  218 +  28  4945 +. 461  203 ±  17  202 +. 53 
5  No  155 +. 8  10,146 +. 657  261 +. 62  163 +  92 
* 1:200 of stock solution. 
:~ 10/tg/m[. 
§ Pooled human myeloma (N. L. Cappel Laboratories)  10 pg/ml. 
¶ Data are expressed as cpm/105 cells +  SEM for triplicate cultures. LANE  ET  AL.  BRIEF  DEFINITIVE  REPORT  337 
cells  in  the  circulation  had  previously  made  detection  of antigen-specific  B  cell 
responses in human peripheral blood extremely difficult. Recent studies have high- 
lighted the critical nature of the kinetics of appearance and disappearance of these 
cells in the circulation in relation to immunization  (10,  14). In  addition, technical 
considerations, such as initial cloning at a high cell density to increase the probability 
of obtaining a rapidly dividing, stable, high-titer antibody-secreting cell line, and the 
use of 30% fetal calf serum along with round-bottomed plates for the limiting dilution 
cloning, were instrumental in the successful establishment of the hybridoma. 
Several  investigators  have  attempted  to  increase  their  yield  of antigen-specific 
hybridomas by culturing with doses of antigen sufficient to cause substantial lympho- 
cyte blastogenesis before fusion (4). In view of the recent data that blastogenic doses 
of antigen may, in fact, suppress rather than enhance specific B cell responses (10), we 
have chosen not to take this approach. However, the ability of submitogenic doses of 
antigen (those doses which induce specific antibody production in vitro) to enrich for 
antigen-specific B cell hybridomas is currently under investigation. 
Although the cell line producing the monoclonal antibody is a  heterohybridoma, 
it is producing pure human Ig. While several of the KLH-specific lines generated in 
the fusion that produced 2F7 were unstable and ceased secreting Ig after several weeks, 
the 2Fv line has remained stable and in continuous culture for the past  10 too. In this 
regard,  others have also  noted stable  as  well as  unstable  antibody-producing lines 
following heterohybridization (8).  Until  stable and  reliably fusable,  HAT-sensitive 
human cell lines become available, heterohybridization should be a perfectly accept- 
able  and  widely  applicable  means  of obtaining  human  monoclonal  antibodies  of 
predefined specificity. The previously reported antigen-specific human  hybridomas 
secreting monoclonal antibodies have used lymph node or spleen as the fusion partner. 
The accessibility of peripheral blood, as opposed to lymphoid organ B cells, enhances 
the general applicability of the method described here. 
The anti-KLH hybridoma antibody was found to be mitogenic for the peripheral 
blood lymphocytes of individuals who had been immunized to KLH but not for the 
lymphocytes of nonimmune individuals. The significance of this finding is not clear 
at present, but may represent stimulation of a subset of immune lymphocytes bearing 
anti-idiotypic receptors as has been described in other systems (15). 
The ability to produce human monoclonal antibodies ofpredefined specificity from 
normal human peripheral blood opens major possibilities for basic as well as applied 
clinical research. Studies of antibody diversity, the roles ofidiotypes and anti-idiotypes 
in immunoregulation, as well as the therapeutic uses of specific antibody should be 
greatly facilitated by the simplicity and clearcut feasibility of this approach. 
Summary 
A  human  IgMk monoclonal antibody, 2Fv, of predetermined specificity, has been 
produced by the fusion of human peripheral blood lymphocytes with the nonsecreting 
mouse myeloma line SP-1. The heterohybridoma has remained stable for over 8 mo, 
with culture supernatants containing up to 30 #g/ml of specific IgM. The antibody 
has been shown to be capable of inducing a  blastogenic response in the absence of 
antigen  in  the  peripheral  blood  lymphocytes of normal  subjects  immune  to  the 
antigen. 
The ability to choose an antigen, immunize, a human subject to that antigen, and 338  LANE ET AL.  BRIEF  DEFINITIVE REPORT 
then  use  the  peripheral  blood  lymphocytes  from  that  subject  to  produce  antigen- 
specific human monoclonal antibodies  should be of great  value in a  wide variety of 
investigative,  diagnostic, and therapeutic endeavors. 
Received  for publication 15 September 1981. 
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